Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Competitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig`s disease

234 views

Published on

Product description The present Competitive Intelligence Report about Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig’s disease provides a competitor evaluation about new treatments in the R&D pipeline of amyotrophic lateral sclerosis (ALS) / Lou Gehrig’s disease as of March 2009. Amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease) is a rapidly progressing, motor neuron disease characterized by the gradual degeneration and death of motor neurons. When muscles in the diaphragm and chest wall fail, patients lose the ability to breathe without ventilatory support. Most people with ALS die from respiratory failure. Approximately 120, 000 new cases are diagnosed each year. No cure has yet been found for ALS. There is one FDA approved drug, riluzole, that modestly slows the progression of ALS. Quite a number of approaches to treat ALS are being investigated in clinical trials: of the 20 different approaches, the majority (16) are small molecule based treatments, followed by biologics such as proteins, peptides and antibodies and more recently cell-based therapies have emerged for clinical testing. Among the targets being clinically tested are glutamate based therapies, antioxidants, cellular energy regulators, immunomodulators and neuroprotective/neurotrophic therapies. Biologic therapies study the neuroprotective effects of VEGF or are directed at the misfolded superoxide dismutase (SOD-1) among other approaches. Cellular therapies intent to induce regeneration of neuronal cells and tissues. The report includes a compilation of current active projects in research and development of small molecules, antibodies, proteins, peptides, vaccines and other biologics including cells for treatment of amyotrophic lateral sclerosis (ALS). In addition, the report lists company-specific R&D pipelines of new treatments of ALS. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. Index Small Molecule Approaches for Treatment of ALS Biologics for Treatment of ALS Cellular Approaches for ALS Therapy Corporate R&D Pipelines of New Treatments for ALS About La Merie

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Competitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig`s disease

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Competitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / LouGehrig`s diseasePublished on March 2009 Report SummaryProduct descriptionThe present Competitive Intelligence Report about Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig’s disease provides acompetitor evaluation about new treatments in the R&D pipeline of amyotrophic lateral sclerosis (ALS) / Lou Gehrig’s diseaseas of March 2009.Amyotrophic lateral sclerosis (ALS, also called Lou Gehrigs disease) is a rapidly progressing, motor neuron disease characterized bythe gradual degeneration and death of motor neurons. When muscles in the diaphragm and chest wall fail, patients lose the ability tobreathe without ventilatory support. Most people with ALS die from respiratory failure. Approximately 120, 000 new cases arediagnosed each year. No cure has yet been found for ALS. There is one FDA approved drug, riluzole, that modestly slows theprogression of ALS.Quite a number of approaches to treat ALS are being investigated in clinical trials: of the 20 different approaches, the majority (16)are small molecule based treatments, followed by biologics such as proteins, peptides and antibodies and more recently cell-basedtherapies have emerged for clinical testing. Among the targets being clinically tested are glutamate based therapies, antioxidants,cellular energy regulators, immunomodulators and neuroprotective/neurotrophic therapies. Biologic therapies study theneuroprotective effects of VEGF or are directed at the misfolded superoxide dismutase (SOD-1) among other approaches. Cellulartherapies intent to induce regeneration of neuronal cells and tissues.The report includes a compilation of current active projects in research and development of small molecules, antibodies, proteins,peptides, vaccines and other biologics including cells for treatment of amyotrophic lateral sclerosis (ALS). In addition, the report listscompany-specific R&D pipelines of new treatments of ALS. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product Category, Indication, R&D Stageand additional comments with a hyperlink leading to the source of information. Index Small Molecule Approaches for Treatment of ALS Biologics for Treatment of ALS Cellular Approaches for ALSTherapy Corporate R&D Pipelines of New Treatments for ALS About La MerieCompetitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig`s disease Page 1/3
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Competitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig`s disease Product Formats Please select the product formats and the quantity you require. 1 User License--USD 250.00 Quantity: _____ Site License--USD 500.00 Quantity: _____ Corporate License--USD 750.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Competitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig`s disease Page 2/3
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Competitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig`s disease Page 3/3

×